Literature DB >> 18155679

Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.

Akin Oni-Orisan1, Lars V Kristiansen, Vahram Haroutunian, James H Meador-Woodruff, Robert E McCullumsmith.   

Abstract

BACKGROUND: Schizophrenia is a chronic, severe mental illness with profound emotional and economic burdens for those afflicted and their families. An increasing number of studies have found that schizophrenia is marked by dysregulation of glutamatergic neurotransmission. While numerous studies have found alterations of postsynaptic molecules in schizophrenia, a growing body of evidence implicates presynaptic factors. Vesicular glutamate transporters (VGLUTs) have been identified and are known to package glutamate into vesicles in the presynaptic terminal for subsequent release into the synaptic cleft. Recent studies have shown that VGLUTs regulate synaptic activity via the amount of glutamate released. Accordingly, we hypothesized that VGLUTs are altered in schizophrenia, contributing to dysfunction of presynaptic activity.
METHODS: Using in situ hybridization and Western blot analysis, we investigated alterations in VGLUT1 and VGLUT2 transcript and protein expression in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and a comparison group.
RESULTS: We found increased VGLUT1 transcript and reduced VGLUT1 protein expression in the ACC, but not DLPFC, in schizophrenia. Vesicular glutamate transporter 2 was unchanged at both levels of gene expression. We did not find changes in VGLUT1 messenger RNA (mRNA) or protein levels following 28-day treatment of rats with haloperidol (2 mg/kg/day), suggesting that our findings in schizophrenia are not due to an effect of antipsychotic treatment.
CONCLUSIONS: Overall, our data suggest decreased glutamate release in the ACC, as well as discordant regulation of VGLUT1 expression at different levels of gene expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155679      PMCID: PMC2669959          DOI: 10.1016/j.biopsych.2007.10.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  78 in total

Review 1.  Functional anatomy of human hippocampal formation and related structures.

Authors:  H Braak; E Braak; D Yilmazer; J Bohl
Journal:  J Child Neurol       Date:  1996-07       Impact factor: 1.987

2.  Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia.

Authors:  W G Honer; P Falkai; C Young; T Wang; J Xie; J Bonner; L Hu; G L Boulianne; Z Luo; W S Trimble
Journal:  Neuroscience       Date:  1997-05       Impact factor: 3.590

3.  Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics.

Authors:  F M Benes; J Davidson; E D Bird
Journal:  Arch Gen Psychiatry       Date:  1986-01

4.  Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study.

Authors:  D P Purohit; M Davidson; D P Perl; P Powchik; V H Haroutunian; L M Bierer; J McCrystal; M Losonczy; K L Davis
Journal:  Biol Psychiatry       Date:  1993-02-15       Impact factor: 13.382

5.  Form and distribution of neurons in rat cingulate cortex: areas 32, 24, and 29.

Authors:  B A Vogt; A Peters
Journal:  J Comp Neurol       Date:  1981-02-01       Impact factor: 3.215

6.  Synaptic termination of thalamic and callosal afferents in cingulate cortex of the rat.

Authors:  B A Vogt; D L Rosene; A Peters
Journal:  J Comp Neurol       Date:  1981-09-10       Impact factor: 3.215

7.  Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia.

Authors:  N I Perrone-Bizzozero; A C Sower; E D Bird; L I Benowitz; K J Ivins; R L Neve
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Varieties and distribution of non-pyramidal cells in the somatic sensory cortex of the squirrel monkey.

Authors:  E G Jones
Journal:  J Comp Neurol       Date:  1975-03-15       Impact factor: 3.215

Review 9.  Recent advances in the phencyclidine model of schizophrenia.

Authors:  D C Javitt; S R Zukin
Journal:  Am J Psychiatry       Date:  1991-10       Impact factor: 18.112

10.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03
View more
  43 in total

Review 1.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

2.  Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia.

Authors:  Adam J Funk; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-08-19       Impact factor: 4.939

3.  Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia.

Authors:  Dan Shan; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

4.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

5.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

6.  Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.

Authors:  Allison S Brandt; Paul G Unschuld; Subechhya Pradhan; Issel Anne L Lim; Gregory Churchill; Ashley D Harris; Jun Hua; Peter B Barker; Christopher A Ross; Peter C M van Zijl; Richard A E Edden; Russell L Margolis
Journal:  Schizophr Res       Date:  2016-02-28       Impact factor: 4.939

Review 7.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

8.  Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters.

Authors:  Lesley A McCollum; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

Review 9.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

10.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  B K Y Bitanihirwe; M P Lim; J F Kelley; T Kaneko; T U W Woo
Journal:  BMC Psychiatry       Date:  2009-11-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.